Hongjie Hu

Ascend is gene to GMP partner with deep expertise in advanced therapy development and commercialization. We offer unparalleled collaboration backed by expertise while working to develop your products from the bench through the clinic and beyond. Let’s build the future of advanced therapies together!

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. Its going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldnt be a direct result of the surgeons state of mind. We believe its possible to create tools that will improve both patient outcome and surgeon experience. We believe its unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europes best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. Were all in. Were still hiring.

Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Based in Boston, Massachusetts and named after the Japanese deity that tamed fire for the good of humanity, Kojin is harnessing groundbreaking discoveries in cell-state and ferroptosis biology to develop first-in-class treatments for use in patients with cancer, and autoimmune and inflammatory diseases, among other disorders. Kojin has developed a drug-discovery platform that integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover therapeutics that specifically modulate ferroptosis, a recently discovered and characterized cell-death mechanism. The Kojin team brings together scientific leadership in chemical biology, genetics, immunology, cancer therapeutics, drug discovery, and clinical development, as well as broad experience in biotechnology entrepreneurship.

Welcome to Akili! At Akili, we believe there is potential for medicine to be developed, delivered and experienced in a completely different way. We’re bringing together world-class neuroscience with exceptional creativity and video game development to challenge the status quo of medicine. Our digital medicine is not delivered through a pill, but rather through a patented and captivating video game experience. Effective medicine that’s captivating and enjoyable to use – now that’s refreshing! Were continuously evaluating new technologies and are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity/ disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. And were always looking for game-changers to join our team – to help us change the status quo of medicine and ignite new hope for those living with cognitive deficits. Imagine what medicine can be®

Welcome to Akili! At Akili, we believe there is potential for medicine to be developed, delivered and experienced in a completely different way. We’re bringing together world-class neuroscience with exceptional creativity and video game development to challenge the status quo of medicine. Our digital medicine is not delivered through a pill, but rather through a patented and captivating video game experience. Effective medicine that’s captivating and enjoyable to use – now that’s refreshing! Were continuously evaluating new technologies and are advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity/ disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases. And were always looking for game-changers to join our team – to help us change the status quo of medicine and ignite new hope for those living with cognitive deficits. Imagine what medicine can be®

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

The LS Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early stage academic research. By partnering with passionate entrepreneurs with transformational science, the LS Polaris Innovation Fund fosters company creation and growth through an active investment model. Our team brings decades of experience in healthcare investing and entrepreneurship. We offer unparalleled guidance and strategic support to early stage companies. This team of proven leaders in scientific research, biopharma, and venture capital investment joined together for the sole purpose of bringing biomedical innovation to the market.

The LS Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early stage academic research. By partnering with passionate entrepreneurs with transformational science, the LS Polaris Innovation Fund fosters company creation and growth through an active investment model. Our team brings decades of experience in healthcare investing and entrepreneurship. We offer unparalleled guidance and strategic support to early stage companies. This team of proven leaders in scientific research, biopharma, and venture capital investment joined together for the sole purpose of bringing biomedical innovation to the market.

AI Fund is a venture studio. We collaborate with entrepreneurs, venture funds, and corporate partners to create great companies that move humanity forward. Founded by Andrew Ng, AI Fund is backed by over $370 million. As a venture studio, we work alongside entrepreneurs, venture funds, and corporate partners to build new companies rapidly and increase their odds of success. The studio is supported by top-tier VCs and partners including Sequoia Capital, NEA, Nikkei, and AES.

Verily Health is a data platform and technology company purpose-built to power AI-enabled precision health. We combine deep clinical, regulatory, and technological expertise to provide our customers with patient-centric solutions that make healthcare more personal and precise. Verily solutions are designed to make healthcare data AI-ready and fit for purpose across care, research, and public health. For more information about Verily please visit: verily.com. Verily is hiring! Check out whats available globally at verily.com/careers.

Verily Health is a data platform and technology company purpose-built to power AI-enabled precision health. We combine deep clinical, regulatory, and technological expertise to provide our customers with patient-centric solutions that make healthcare more personal and precise. Verily solutions are designed to make healthcare data AI-ready and fit for purpose across care, research, and public health. For more information about Verily please visit: verily.com. Verily is hiring! Check out whats available globally at verily.com/careers.

AI Fund is a venture studio. We collaborate with entrepreneurs, venture funds, and corporate partners to create great companies that move humanity forward. Founded by Andrew Ng, AI Fund is backed by over $370 million. As a venture studio, we work alongside entrepreneurs, venture funds, and corporate partners to build new companies rapidly and increase their odds of success. The studio is supported by top-tier VCs and partners including Sequoia Capital, NEA, Nikkei, and AES.

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, Principal and Planetary Health Investments teams, Novo Holdings invests in life science companies at all stages of development.

Ascend is gene to GMP partner with deep expertise in advanced therapy development and commercialization. We offer unparalleled collaboration backed by expertise while working to develop your products from the bench through the clinic and beyond. Let’s build the future of advanced therapies together!

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. Its going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldnt be a direct result of the surgeons state of mind. We believe its possible to create tools that will improve both patient outcome and surgeon experience. We believe its unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europes best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. Were all in. Were still hiring.

Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.